Jianshi Technology-B (09877) announced results for the year ended December 31, 2023, other revenue and revenue...
According to the Zhitong Finance App, Jianshi Technology-B (09877) announced results for the year ended December 31, 2023, with other revenue and revenue of RMB 43.828 million (same unit); R&D expenses of RMB 288 million; loss attributable to shareholders of RMB 372 million, a year-on-year decrease of 15.38%; and loss per share.
The company has set up a professional and efficient commercialization team to carry out early market introduction and education of core products. The company's clinical medical team formed a professional support team with medical literacy and understanding of procedures, and established global surgical standards through high standards of clinical support and feedback. At the same time, the marketing team has begun preliminary work on product admission and the construction of a regional distributor network to enhance the company's market expansion and marketing capabilities to further enhance commercialization capabilities.
The company has expanded more than 220 influential hospitals in academia and industry in the LUX-Valve series of products, covering more than 30 provinces, municipalities and autonomous regions across the country.
The company has successfully completed the promotion of LUX-Valve Plus implant surgery or therapy in nearly 50 hospitals around the world other than China, covering influential hospitals in North America, Europe, Asia Pacific, Latin America and other regions.
The company has participated in high-quality academic conferences in the field of structural heart disease such as industry conferences, associations, and annual meetings at home and abroad to promote the establishment of brand awareness and increase the market popularity of the company's products. Through academic conferences and events, the company's products have received wide recognition from around the world, and it has also helped the company expand resources such as hospitals, doctors, sales networks, supply chains, and potential partners ahead of time for recent and future global commercialization.